EN
Home/Answers/Wearing off before the next dose
ALLAll countries Medicines

Do tirzepatide and semaglutide wear off before the next dose?

What we checked14 sources, each one opened and linked to the sentence it supportsLast checked Nov 9, 2026 · Next review due Nov 9, 2027 · How we write
The short answer

Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) levels do fall between weekly doses. The US Zepbound and Wegovy labels give half-lives of about 5 to 6 days and about 1 week. By our estimate, the level before the next dose is about half the peak. We found no study showing that this drop causes late-week hunger.

Do tirzepatide and semaglutide levels really fall before the next dose?

Yes, levels rise and fall each week, but the medicine does not clear between doses, so some is always in your body.12

The US Zepbound label gives tirzepatide a half-life (time for the level to halve) of about 5 to 6 days.1 The US Mounjaro label and the UK Mounjaro SmPC say about 5 days.34 On the Zepbound label, it peaks about 24 hours after an injection.1

The US Wegovy label gives semaglutide a half-life of about 1 week.2 Its peak comes 1 to 3 days after the injection.2

We worked out the fall from those half-lives, counting from a peak one day after the injection. At a steady level, the amount just before the next dose is roughly half the peak.12 That is our estimate for an average person, not a blood measurement. On the US Zepbound label, levels steady after 4 weeks, so they are still building before then.1

For once-daily Wegovy tablets, the EU product information says a long half-life and daily dosing reduce day-to-day level swings.6

Does a falling level explain late-week hunger?

It may, but we found no study that tracked hunger across the days between doses, so the link is not proven.

The US Zepbound and Wegovy labels say these medicines lower calorie intake, likely by affecting appetite.12 Those labels mention hunger only as a sign of low blood sugar.12

A 20-week trial of semaglutide 2.4 mg measured appetite and a test lunch the day after the final dose.7 That is close to peak level.2 It cannot show what happens at the end of the week.

Can a higher dose or a different schedule change it?

The US Zepbound label sets a weekly schedule, and no label we read describes a shorter gap as a way to treat late-week hunger.1

On the US Zepbound label, the dose rises in 2.5 mg steps after at least 4 weeks on the current dose.1 On the US Zepbound label, 2.5 mg is for starting treatment and is not approved as a maintenance dose.1 The maximum is 15 mg once weekly.1 The US Wegovy label sets a maximum of 7.2 mg once weekly, after at least 4 weeks on 2.4 mg.2 Tirzepatide exposure rises in step with the dose, so a higher dose lifts the level across the week.1

We found no study testing whether that eases late-week hunger. Most nausea, vomiting and diarrhoea happened during dose increases, the US Zepbound label says.1

Labels allow moving the injection day if necessary.15 The US Zepbound label and UK Wegovy SmPC require at least 3 days between the two doses.15 After the change, the UK Wegovy SmPC says once-weekly dosing should continue.5

Why might the effect fade over weeks or months?

In trials, weight loss levelled off for most people, and one study of another medicine found appetite climbing as weight fell.89

In SURMOUNT-1, about 88% to 90% of people on tirzepatide reached a plateau by week 72, across body-size groups.8 A plateau meant less than 5% weight change over a 12-week period and every later one.8 The UK Wegovy SmPC says mean weight in STEP 5 fell until week 68, then levelled off.5

One study used canagliflozin, a diabetes medicine that causes weight loss.9 It estimated that people ate about 100 kcal more each day for every kg lost.9

We found no study showing tolerance to the appetite effect.

What do people on tirzepatide or semaglutide report about wear-off?

From public patient forums: about 642 Reddit threads in r/Zepbound, r/Mounjaro, r/mounjarouk, r/Semaglutide, r/WegovyWeightLoss and r/WegovyPillWeightLoss, read October 2025 to October 2026. Personal reports, not medical evidence. The threads were chosen for this topic, so they cannot show how common wear-off is.

What people describe

  • Not studied Many say hunger or food noise returns before the next weekly dose, most often around days 4 to 7. A few report the opposite, with hunger highest around shot day. We found no study of hunger across the dosing week.
  • Not studied Several say a dose works at first and then seems to fade over weeks or months, sometimes with a stall. Trials show weight loss levelling off over many months, but we found no study of a dose fading this way.85
  • Not studied Several link hungrier spells to periods, perimenopause or other hormonal changes. We found no study in people. One rat study linked semaglutide's effect on food intake to the oestrous cycle, the rat reproductive cycle.10
  • Not studied Several say the late-week dip eased at a higher dose. Several others say it continues at high doses or after long-term use. We found no study of this.
  • Not studied A few on daily tablets describe hunger rising in the evening. We found no study of this.

Advice people share

  • Label says otherwise Many posts mention splitting a dose or injecting more often than labelled. Several mention stretching the gap or drawing non-standard doses from pens. The US Zepbound and Wegovy labels set one injection once weekly.12
  • Matches the label Several say to give each dose about 4 weeks before moving up. The US Zepbound label requires at least 4 weeks on a dose before an increase.1
  • Matches the label Several suggest rotating the injection site, though people disagree on whether it affects the dip. The US Zepbound and Wegovy labels say to rotate sites with each dose, and report similar exposure in the abdomen, thigh or upper arm.12
  • Not studied Many suggest protein, fibre, fluids, filling foods or planned snacks on hungry days. We found no study of these for late-week hunger.

In your country

Across the labels we opened, weekly dosing and the fall in level between doses are the same, but the brands sold and the minimum gap for moving an injection day differ by country.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The answer above applies.

Emergency number: 000

Side effects and risks in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: When moving the injection day, Canada's Ozempic monograph sets at least 2 days between the two doses. Its Wegovy monograph sets at least 3 days.1213

Emergency number: 911

Side effects and risks in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The answer above applies.

Emergency number: 15 or 112

Side effects and risks in France

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 112

Side effects and risks in Germany

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We did not open an Indian label for this page, so it relies on the US labels and the UK and EU product information.

Emergency number: 112

Side effects and risks in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We did not open a Saudi label for this page, so it relies on the US labels and the UK and EU product information.

Emergency number: 997 or 911

Side effects and risks in Saudi Arabia

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We did not open a UAE label for this page, so it relies on the US labels and the UK and EU product information.

Emergency number: 998 for an ambulance, or 999

Side effects and risks in the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 999

Side effects and risks in the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: When moving the injection day, the US Ozempic label and the US Wegovy Medication Guide set 2 days between doses. The US Zepbound and Mounjaro labels set at least 3 days.11213

Emergency number: 911

Side effects and risks in the US

Get help now: call your local emergency number Severe abdominal pain or pressure, chest pain or discomfort lasting 2 minutes or more, breathing problems, fainting, a change in mental status, severe or persistent vomiting or diarrhoea, or feeling suicidal are emergency warning signs, according to the American College of Emergency Physicians.14 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

If you do not need emergency care, contact your prescriber or a doctor right away if vomiting or diarrhoea will not go away, or for gallbladder symptoms such as upper stomach pain, fever, yellowing of the skin or eyes, or clay-coloured stools.1 The US Zepbound Medication Guide says to stop the medicine and call right away for severe stomach-area pain that will not go away.1 Hunger with shakiness, sweating or dizziness can be signs of low blood sugar, and the risk may be higher with insulin or a sulfonylurea. Report these signs to your prescriber.1 Confusion is an emergency sign, as listed above.14

Read the full picture

Related questions

Did this answer your question?

Sources

  1. US Zepbound (tirzepatide) prescribing information and Medication Guide, revised August 2026. Eli Lilly
  2. US Wegovy (semaglutide) prescribing information and Medication Guide, revised June 2026. DailyMed
  3. US Mounjaro (tirzepatide) prescribing information. Eli Lilly
  4. UK Mounjaro KwikPen (tirzepatide) SmPC. emc
  5. UK Wegovy 2.4 mg FlexTouch (semaglutide) SmPC. emc
  6. EU Wegovy (semaglutide) product information, tablet section 5.2. European Medicines Agency
  7. Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. Most authors work for Novo Nordisk. Europe PMC full text
  8. Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025;15(3):e12734. Post-hoc analysis funded by Eli Lilly. Journal article · Europe PMC full text
  9. Polidori D, et al. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity. 2016;24(11):2289-2295. Journal article · Europe PMC record
  10. Applebey SV, et al. The estrous cycle moderates the food and body weight suppressive effects of glucagon-like peptide-1 receptor agonism. Diabetes Obes Metab. 2026;28(1):221-230. Rat study. PubMed · Europe PMC record
  11. US Ozempic (semaglutide) prescribing information, revised May 2026. DailyMed
  12. Canadian Ozempic (semaglutide) Product Monograph. Health Canada Drug Product Database
  13. Canadian Wegovy (semaglutide) Product Monograph. Health Canada Drug Product Database
  14. MedlinePlus, US National Library of Medicine. Recognizing medical emergencies, giving the American College of Emergency Physicians' warning signs. medlineplus.gov

Last checked Nov 9, 2026 · Next review due Nov 9, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 9, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write